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Editorial
The Quest for Conquering COVID-19:
Updates from the Laboratory
David B. Nash, MD, MBA
As I write, a 1-year anniversary that calls for no cele-bration has arrived. On January 20, 2020, the state of
Washington and the Centers for Disease Control and Pre-
vention diagnosed the first US case of the highly contagious
virus we’ve come to know as COVID-19. Sadly, the pan-
demic death toll (now more than 420,000 Americans) is ex-
pected to climb even higher.
For a full year, the urgent needs and complex challenges
associated with the pandemic have dominated the news and
demanded constant attention from policy makers, the sci-
entific community, and the health care industry. Confronting
this new virus has required unprecedented effort on the part
of scientists charged with developing and distributing di-
agnostic tests and vaccines, and frontline clinicians re-
sponsible for saving lives.
Although many hurdles have been cleared, other issues
have yet to be resolved. For instance, we still don’t have
tests appropriate for population screening purposes that
could be administered at points of care (eg, schools). What
we need today is a reasonably priced, easily accessed anti-
gen test that can be self-administered with results in minutes
rather than days.
We also need what only science can provide – ongoing
research that constantly expands our understanding of this
novel organism, improves our ability to manage its spread,
and helps reduce the propagation of misinformation.
Last year, it came to my attention that Quest Diagnostics,
a large American clinical laboratory, had taken a leading
role in the global fight against COVID-19. In my estimation,
their scientific and research staff rival that of many top
universities and their work likely will have a positive impact
on combatting this and future outbreaks. The collection of
reports and analyses contained in this supplement provide
useful point-in-time analyses and insights into effective
testing, population screening strategies, and interventions
for the near future.
The monumental task of getting Americans back to work
will fall squarely on the shoulders of the nation’s employers,
most of whom are woefully unprepared for this role. Here,
Quest is emerging as a national leader in helping to guide
employer-based return to work strategies that incorporate the
best available evidentiary-based recommendations. Two of the
articles in this supplement focus on the evolving role of em-
ployers in the longer-term national response to the pandemic.
1. In their article, Return to Work: Managing Employee
Population Health During the COVID-19 Pandemic,
Fragala et al discuss how employers have responded
to the health crisis by means of transforming bene-
fits plans to address immediate needs and introduc-
ing targeted strategies such as ongoing testing/
surveillance and workplace modifications to keep
workforces healthy.
2. Plantes et al present an overview of the peer-reviewed
literature in their article, Model for Mitigation of
Workplace Transmission of COVID-19 Through
Population-based Testing and Surveillance. They de-
scribe an approach that uses a biometric platform in-
formed by real-time PCR test data at the county and
subcounty levels. Bioinformatics tools can be used by
large employers to mitigate the impact of the pan-
demic on their workplaces.
The rapid spread of COVID-19 has focused attention
on the need for safe, convenient, timely, and scalable
methods for collecting respiratory specimens for testing.
In their article, Evolution of Specimen Self-Collection in
the COVID-19 Era: Implications for Population Health
Management of Infectious Disease, Cockerill et al dis-
cuss the current and future state of self-collection for
infectious agents and the impacts of these approaches on
population health management, disease diagnosis, and
prevention. For instance, self-collection will help prevent
the spread of the disease by eliminating the need for
physical contact between the patient and health care
providers.
The jury is still out on the question of whether and how
long an immune response persists following infection
with COVID-19. Insights from Patterns of SARS-CoV-2
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points toward a possible answer. Based on their assess-
ment of patterns of immunoglobulin G (IgG) positivity
over time in individuals tested for SARS-CoV-2 ribo-
nucleic acid or IgG positivity (more than 2.4 million
SARS-CoV-2 IgG serology and 6.6 million acid ampli-
fication test results), Kaufman et al draw some conclu-
sions about how some individuals may be infecting
household members.
The breadth of the pandemic’s ripple effect will be re-
vealed over time. Niles et al have uncovered some dis-
turbing trends stemming from the simultaneous opioid
epidemic and COVID-19 pandemic. The Opioid Epidemic
Within the COVID-19 Pandemic: Drug Testing in 2020
describes their analysis of changes in clinical drug testing
patterns and results. They found a decrease in overall drug
testing with increased positivity for high-risk drugs and
dangerous drug combinations – patterns that, if persistent,
will lead to an increased need for health care and public
health resources dedicated to supporting vulnerable patients
and addressing causes.
Conquering COVID-19 will require many more combat-
ants over an extended period of time but, as exemplified in
these reports, Quest Diagnostics is helping to lead the charge!
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